GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults
Obese adults taking GLP-1 drugs showed 41% lower risk of obesity-related cancers versus counseling alone, suggesting potential cancer prevention beyond weight loss.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Survodutide in adults with obesity and metabolic…
Survodutide markedly reduced liver fat and weight in people with fatty liver disease, offering a promising new treatment option for this currently drug-limited condition.
Novel or significantly improved treatmentSeptin multimer autoantibodies in severe motor neuropathy mimicking…
Researchers identified a treatable autoimmune nerve condition that can mimic ALS, offering hope for patients previously thought to have untreatable motor neuron disease.
Near-term implementable findingHigh-risk cytogenetic abnormalities impact the cytological and…
Certain genetic subtypes within a favorable leukemia type behave differently, helping doctors tailor treatment intensity and monitoring for individual patients.
Underserved or high-risk populationsCancer Prevalence Among Large Cohort of Individuals With Down Syndrome
New large-scale data on cancer patterns in Down syndrome reveals why standard screening guidelines don't fit this population, enabling tailored prevention strategies.